Abstract 578P
Background
This study aimed to describe efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for elderly patients (≥65 years) with treatment-naïve EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Methods
Patients with treatment-naïve EGFR-mutated advanced NSCLC were enrolled at several hospitals in Taiwan between May 2014 and January 2018. Patient characteristics, including age, sex, performance status (PS), smoking history, tumor morphology, mutation type, stage, metastasis, efficacy and safety of EGFR-TKIs were compared. Univariate and multivariate analyses were performed to explore possible prognostic factors.
Results
This study enrolled 1,343 patients with treatment-naïve EGFR-mutated advanced NSCLC, of which 554 were aged <65 years, 383 were aged 65–74 years, 323 were aged 75–84 years, and 83 were aged ≥85 years. In elderly patients, afatinib showed significantly better efficacy, with a median progression-free survival (PFS) of 14.7 months and overall survival (OS) of 22.2 months, than gefitinib (9.9 months and 17.7 months, respectively) and erlotinib (10.8 months and 18.5 months, respectively; PFS: p=0.003; OS: p=0.026). However, patients treated with afatinib also experienced more grade ≥3 adverse events than those treated with gefitinib and erlotinib, including skin toxicities (6.1% vs. 1.8% vs. 3.9%, p=0.052), paronychia (5.1% vs. 0.5% vs. 2.3%, p=0.006), mucositis (1.9% vs. 0% vs. 1.1%, p=0.122), and diarrhea (9.3% vs. 2.3% vs. 1.5%, p<0.0001). PS of 2-4, stage IV disease, liver, bone, pleura, adrenal, and pericardial metastases, and EGFR-TKI treatment with gefitinib were associated with poor PFS, while age of ≥ 85 years, PS of 2-4, stage IV disease, liver, brain, bone, pleura, adrenal, and pericardial metastases, and EGFR-TKI treatment with gefitinib were associated with poor OS. These factors were independent prognostic factors for both PFS and OS.
Conclusions
For elderly patients with EGFR-mutated advanced NSCLC, afatinib was associated with better efficacy than gefitinib or erlotinib in elderly patients with EGFR-mutated advanced NSCLC as a first-line treatment with acceptable AEs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract